Loading
Englumafusp alfa is an experimental fusion protein from Hoffmann-La Roche in phase 2 trials for hodgkin lymphoma, aimed at CD19.
Englumafusp alfa (RO7227166) is a fusion protein developed by Hoffmann-La Roche. Its target is CD19 (the sponsor names CD19 x 4-1BBL). The sponsor states: Englumafusp alfa (RO7227166) is a CD19-targeted 4-1BB ligand fusion protein that costimulates T cells, given by intravenous infusion three-weekly in combination with obinutuzumab and/or glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma. ClinicalTrials.gov describes the intervention as: Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT04077723, plans to enrol 498 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Englumafusp alfa (RO7227166) is a CD19-targeted 4-1BB ligand fusion protein that costimulates T cells, given by intravenous infusion three-weekly in combination with obinutuzumab and/or glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma. Connects to CD19.
1.Englumafusp alfa binds CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Englumafusp alfa" OR ABSTRACT:"Englumafusp alfa" OR TITLE:"RO7227166" OR ABSTRACT:"RO7227166" OR TITLE:"A CD19 Targeted 4-1BB Ligand; RO7227166" OR ABSTRACT:"A CD19 Targeted 4-1BB Ligand; RO7227166") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Englumafusp alfa, not a curated reading list.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19 and the tag pipeline.